ClinicalTrials.gg
CompletedNCT04341454Updated Dec 21, 2021

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis

A Phase 3 interventional study of DWP14012 X mg and DWP14012 X mg placebo in Acute Gastritis and Chronic Gastritis, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-12-21.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.

Enrollment
8th of 25
327 · median 242
Started
2020
with 3 others
Phase 3
10 of 32
none open now
Registered
21st of 32
by date
Lead sponsor
5 of 32
Daewoong Pharmaceutical Co. LTD.

Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2020, is one of 10 in phase 3, and was the 21st registered.

Gastritis

135 studies on the registry are indexed under Gastritis; 23 are open to participants now.

Browse Gastritis studies →

Open to participants now

3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Gastritis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of study is to confirm the efficacy of DWP14012 X mg QD, DWP14012 Y mg BID compared to placebo in patients with Acute or Chronic Gastritis

Read the detailed description

This study was designed as a multi-center, randomized, double-blind, placebo-controlled, parallel-group, phase 3 study to assess the efficacy and safety of oral administration of DWP14012 X mg QD, Y mg BID and placebo for 2 weeks in patients with acute and chronic gastritis.

03

Conditions studied

  • Acute Gastritis
  • Chronic Gastritis

Browse trials for

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 19 and 75 years old based on the date of written agreement
  • Those who are diagnosed with acute or chronic gastritis with at least one erosion observed on upper gastrointestinal endoscopy
  • Those who had experienced one or more subjective symptoms of gastritis

Exclusion criteria

Exclusion Criteria:

  • Those who have had surgery to reduce gastric acid secretion, or gastric or esophageal surgery
  • Those with history of hepatic, renal, neurologic, pulmonary, endocrine, hematologic, cardiovascular or genitourinary disease that could affect the study results
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    DWP14012 X mg QD

    * Morning: 1 tablet of DWP14012 X mg + 1 tablet of DWP14012 Y mg placebo * Evening: 1 tablet of DWP14012 Y mg placebo

    Drug: DWP14012 X mg · Drug: DWP14012 Y mg placebo

  • Experimental
    DWP14012 Y mg BID

    * Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg * Evening: 1 tablet of DWP14012 Y mg

    Drug: DWP14012 X mg placebo · Drug: DWP14012 Y mg

  • Placebo comparator
    placebo

    * Morning: 1 tablet of DWP14012 X mg placebo + 1 tablet of DWP14012 Y mg placebo * Evening: 1 tablet of DWP14012 Y mg placebo

    Drug: DWP14012 X mg placebo · Drug: DWP14012 Y mg placebo

Interventions

  • DWP14012 X mg, tablet, orally, once daily for 2 weeks

  • DrugDWP14012 X mg placebo

    DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks

  • DWP14012 Y mg, tablet, orally, twice daily for 2 weeks

  • DrugDWP14012 Y mg placebo

    DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks

06

What researchers measure

Primary outcomes

  1. Improvement rate of gastric mucosal erosion

    Improvement rate (%) = (Number of effective cases(change of ≥ 50% in erosion score) / Number of target cases) x 100

    Time frame: at 2 weeks after the IP administration

Secondary outcomes

  1. Cure rate of gastric mucosal erosion

    Cure rate (%) = (Number of healed cases(0 erosions) / Number of target cases) x 100

    Time frame: at 2 weeks after the IP administration

  2. Cure rate of gastric mucosal edema

    Cure rate (%) = (Number of healed cases(change of 2 to 1 in edema score) / Number of target cases) x 100

    Time frame: at 2 weeks after the IP administration

  3. Improvement rate of gastric mucosal erythema

    Improvement rate (%) = (Number of effective cases(change of ≥ 50% in erythema score) / Number of target cases) x 100

    Time frame: at 2 weeks after the IP administration

  4. Improvement rate of gastric mucosal bleeding

    Improvement rate (%) = (Number of effective cases(change of ≥ 50% in bleeding score) / Number of target cases) x 100

    Time frame: at 2 weeks after the IP administration

  5. Improvement rate of subjective symptoms

    Improvement rate (%) = (Number of effective cases(change of ≥ 50% in subjective symptom score) / Number of target cases) x 100

    Time frame: at 2 weeks after the IP administration

07

Study locations

1 site
  • Hanyang University Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Aug 2021, 14 months.

Of 11 phase 3 interventional studies under Gastritis, half reached primary completion within 6 months of starting (the median); a quarter within 4 and three quarters within 17. This study's 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 10, 2020
StartActual
Jun 2, 2020
Primary completionActual
Aug 4, 2021
CompletionActual
Sep 16, 2021
Last update
Dec 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04341454
Responsible party
Sponsor
First posted
Apr 10, 2020
Start date
Jun 2, 2020
Primary completion
Aug 4, 2021
Completion
Sep 16, 2021
Last update
Dec 21, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion